Where To Next? Tigenix Investors Have New Stem Cell Options – Seeking Alpha
Seeking Alpha |
Where To Next? Tigenix Investors Have New Stem Cell Options
Seeking Alpha After our recent article on Tigenix (TIG) in which we postulated that their Phase III success in treating Crohn’s related fistulas with stem cell therapeutic Alofisel would result in EU marketing approval we have seen a flurry of excitement in the … |
|
UPDATE 1-Drugmakers see a pricing blueprint in an $850000 gene therapy
Reuters “We’re laying the groundwork for the future of our pipeline and the future of one-time curative gene therapy treatments,” Spark’s chief executive officer, Jeffrey Marrazzo, said in an interview at the JPMorgan Healthcare Conference in San Francisco … |
MIT Technology Review |
Gene Therapy Could Make Cancer Care More Unequal, and This Map Shows Why
MIT Technology Review Two new cancer treatments have shown miraculous cures, but if you happen to live in Arkansas or Montana, or a handful of other rural states—let alone outside the U.S.—you’ll have to travel hundreds of miles to get them. And it’s by no means certain … |
Forbes |
Non-Profit Says $850000 Gene Therapy Is At Least Twice As Expensive As It Should Be
Forbes Earlier this month, Spark Therapeutics announced that its gene therapy Luxturna, for a rare form of blindness, would cost $850,000 a year. The price was below the $1 million-plus price tag many had expected, and was called fair by the chief medical … Spark’s planned price for Luxturna gene therapy for rare blindness too high: ICERReuters Payers point to Spark’s gene therapy as a model for innovative pricing plansFiercePharma At $850000, price for new childhood blindness gene therapy four times too high, analysis saysSTAT |
Mainline Today |
Immunotherapy Gave this Upper Darby Woman a Second Chance at Life
Mainline Today How does that happen and why can’t immune systems kill cancer cells? Those questions are the foundation of immunotherapy, a field that focuses on boosting immune systems so they can fight cancer. At the time Kelly started to deteriorate, a new immuno … |
National Institutes of Health (press release) |
The coming of age of gene therapy: A review of the past and path forward
National Institutes of Health (press release) After three decades of hopes tempered by setbacks, gene therapy—the process of treating a disease by modifying a person’s DNA—is no longer the future of medicine, but is part of the present-day clinical treatment toolkit. The Jan. 12 issue of the … |
|
FDA roadmap highlights opioids, gene therapy, biosimilars
BioPharma Dive The Food and Drug Administration’s 2018 strategic policy roadmap highlights the battle against opioid addiction, the growth of cell and gene therapy, and using competition to improve access and make drugs more affordable. Identifying where pharma is … |